Navigation Links
STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Date:1/15/2008


PARIS, January 15 /PRNewswire-FirstCall/ --

(EURO Millions) 2007 2006 07/06

% % %

Sales Sales Change

Southern Europe(1) 31.99 74.3 27.97 74.7 14

Other EU Countries (2) 9.66 22.4 8.22 22.0 17

Other Markets 1.40 3.3 1.27 3.3 10

SLIT 34.55 80.3 28.75 76.8 20

SCIT 7.12 16.5 6.86 18.3 4

Other Products 1.38 3.2 1.85 4.9 (25)

Total Q4 Sales 43.05 100.0 37.46 100.0 15

Southern Europe (1) 109.15 74.2 93.68 74.0 17

Other EU Countries (2) 32.49 22.1 28.00 22.1 16

Other Markets 5.42 3.7 4.87 3.9 11

FY Sales 147.06 100.0 126.55 100.0 16

SLIT 116.43 79.2 96.30 76.1 21

SCIT 24.90 16.9 24.09 19.0 3

Other Products 5.73 3.9 6.16 4.9 (7)

FY Cumulated Sales 147.06 100.0 126.55 100.0 16

(1) Portugal, Spain, France, Italy, Greece; (2) including Switzerland

Sales growth and financial position

2007 4th quarter sales registered a further 15% growth in all markets. 2007 full-year growth was 16%, driven by the strength of the sublingual route desensitisation segment (SLIT), which grew 21%. The significant increase in the number of new patients, in particular in France and Germany, and growing sales excluding subsidiaries were the main growth drivers.

2007 results, should exceed those of 2006 (EBIT of EUR 23 million), in spite of a further significant increase in R&D expenses.

2008 outlook

The Group gives guidance of double-digit sales growth. 2008 results should be impacted by additional R&D investments in the US.

The questions asked by the German agency regarding the ORALAIR(R) Grasses file have been dealt with and we expect a licence to be issued.

Talks are continuing with potential partners in the US.

About STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

StallergEnes realised 2007 sales of EUR 147 million, of which half outside France.

StallergEnes' shares are listed on Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on StallergEnes, please visit our website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
2. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
3. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
4. SAFC Hitech(TM) Plans Further Expansion Into Asia
5. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
6. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
7. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
10. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
11. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):